BioSpace News Archive

ITM Medical Isotopes GmbH and Isogen signed a formal supply arrangement to provide a reliable supply of Lutetium-177 to the world’s health care system using Bruce Power reactors as a key supply source.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. The data from this long-term extension study show that, relative to previous Phase 2 study results of CTP-543, hair regrowth asses

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that it proposes to offer, subject to market conditions and other factors, $650 million aggregate principal amount of senior notes due 2031 (the “Notes”). The Notes will be offered and sold only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”),

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter 2020 on Tuesday, November 17, 2020. The Company has scheduled a conference call for that same day, Tuesday, November 17, 2020 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing: US Tol

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 5, 2020 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2020.

Results reinforce that ruxolitinib cream treatment results in a rapid, substantial and sustained reduction in itch - Results also demonstrate improvement in patient-reported perceptions of sleep quality, sleep depth and restoration associated with sleep as measured by the PROMIS ® Short Form-Sleep Disturbance (8b) questionnaire - Oral presentation will be available on-demand as part of the 29th EADV Virtual Congress

Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care

Approval of new name marks important branding milestone and aligns with the program’s overall progress REQORSA immunogene therapy uses the company’s unique, proprietary ONCOPREX™ nanoparticle delivery system to deliver cancer-fighting genes FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® for the treatment of non-small cell lung cancer earlier this year

Shattuck Labs, Inc. (“Shattuck”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its presentation at the CD47|SIRPα Summit 2020 being held virtually November 4-5, 2020. Presentation Details Presentation Title: CD40 Enhances Type I Interferon